



## Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.  
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243  
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

March 15, 2019

To,  
Dept. of Corporate Services  
**BSE Limited**  
P.J. Towers, Dalal Street,  
Mumbai – 400 001

**Sub: Buyback of equity shares by Natco Pharma Limited (the “Company”) from Open Market using stock exchange mechanism**

This is in reference to the captioned subject and our letter dated November 9, 2018, submitting the Public Announcement dated November 6, 2018 ("**Public Announcement**"). A Corrigendum to the Public Announcement ("**Corrigendum**") dated March 14, 2019 was made by the Company to the Eligible Shareholders about the SEBI press release dated December 3, 2018 as well as the BSE notice no. 20190311-12 dated March 11, 2019 that requests for effecting transfer of securities shall not be processed unless the securities are held in the dematerialised form with a depository, has been published on March 15, 2019 in the following newspapers:

1. Business Standard (Hindi and English) (All Editions)
2. Nava Telangana (Telugu) (Regional Edition)

In pursuance to the above, please find enclosed a copy of the Corrigendum published in Business Standard (English) (Mumbai Edition) on March 15, 2019.

The Corrigendum is to be read in conjunction with the Public Announcement dated November 6, 2018.

Capitalized terms not defined herein shall have the same meaning as assigned to such terms in the Public Announcement and the Corrigendum.

Kindly take the same on record.

Yours faithfully,  
**For Natco Pharma Limited**

M Adinarayana  
Company Secretary &  
Vice President (Leal & Corp Affairs)

Encl.: a/a



**NATCO PHARMA LIMITED**

**Corporate Identification Number (CIN): L24230TG1981PLC003201**

**Registered Office:** Natco House, Road No. 2, Banjara Hills, Hyderabad – 500 034,  
Telangana, India

**Telephone:** +91 040 2354 7532, **Fax:** +91 040 2354 8243

**Website:** www.natcopharma.co.in

**Email:** investors@natcopharma.co.in

**Company Secretary and Compliance Officer:** Mr. M. Adinarayana

**CORRIGENDUM TO THE PUBLIC ANNOUNCEMENT DATED NOVEMBER 6, 2018 FOR THE ATTENTION OF THE EQUITY SHAREHOLDERS / BENEFICIAL OWNERS OF EQUITY SHARES OF NATCO PHARMA LIMITED (“COMPANY”) FOR THE BUY-BACK OF EQUITY SHARES FROM THE OPEN MARKET THROUGH STOCK EXCHANGES UNDER THE SECURITIES AND EXCHANGE BOARD OF INDIA (BUY-BACK OF SECURITIES) REGULATIONS, 2018 (“SEBI BUY-BACK REGULATIONS”).**

This Corrigendum dated March 14, 2019 (the “**Corrigendum**”) is in continuation of and should be read in conjunction with the Public Announcement dated November 6, 2018 (“**Public Announcement**”) made by the Company. Capitalized terms used in this Corrigendum and not defined herein shall have the same meaning as ascribed in the Public Announcement. The Equity Shareholders of the Company are requested to note the following changes/ amendments to the Public Announcement:

1. In the Section titled “PROCESS AND METHODOLOGY TO BE ADOPTED FOR THE BUY-BACK” in Paragraph 12.9 viz., Procedure for Buy-back of Physical Shares”, the following paragraph shall be included in addition to the existing disclosure and form part of the Public Announcement:

“As per the proviso to regulation 40(1) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (notified by the Securities and Exchange Board of India (“SEBI”) vide the SEBI (Listing Obligations and Disclosure Requirements) (Fourth Amendment) Regulations, 2018 dated June 8, 2018), read with press release dated December 3, 2018 issued by SEBI, post April 1, 2019 requests for effecting transfer of securities shall not be processed unless the securities are held in the dematerialised form with a depository. BSE Limited vide notice no. 20190311-12 dated March 11, 2019, intimated the discontinuation of settlement of trade obligations in “Physical Delivery” mode for Buy-back of Equity Shares w.e.f. March 25, 2019. Therefore, requests for effecting transfer of securities on or after March 25, 2019 or such extended date as may be notified by the SEBI and/or the Stock Exchanges (SEs) shall not be processed unless the securities are held in the dematerialised form with a depository.”

2. In Paragraph 12.10.1 of the Public Announcement the words “*The Physical Share Buy-back Window shall remain open during the Buy-back period, for the Buy-back of physical shares.*” shall be substituted by the following:

M. Adinarayana




“The Physical Share Buy-back Window shall remain open for such period as prescribed under the SEBI Buy-back Regulations or such shorter period as may be prescribed by SEBI and / or the Stock Exchanges.”

This Corrigendum is available on the Company’s website (www.natcopharma.co.in) and is expected to be available on the website of SEBI (www.sebi.gov.in) during the Buy-back Period.

### 3. DIRECTORS’ RESPONSIBILITY

As per Regulation 24(i)(a) of the SEBI Buy-back Regulations, the Board accepts responsibility for the information contained in this Corrigendum and confirms that it contains true, factual and material information and does not contain any misleading information.

**For and on behalf of the Board of Directors of Natco Pharma Limited**

 <b>V C Nannapaneni</b> <b>Chairman and Managing Director</b> <b>DIN: 00183315</b>	 <b>Rajeev Nannapaneni</b> <b>Vice Chairman and Chief Executive Officer</b> <b>DIN: 00183872</b>	 <b>M. Adinarayana</b> <b>Company Secretary and Compliance Officer</b> <b>M. No.: F3808</b>
---	---	--

**Date:** March 14, 2019

**Place:** Hyderabad